DOCSLIB.ORG

20080626 Trading Notice Functional 0076

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
20080626 Trading Notice Functional 0076 Trading Notice – 0076 Date: 26 th June 2008 Priority: Notification Bulletin Subject: Chi-X expands the Danish and Norwegian guaranteed stock universe to include all OMX Copenhagen 20 and OBX 25 constituents Sent from: Trading Operations Message: Chi-X Europe Ltd (Chi-X) is pleased to announce that, following successful completion of trading in selected Danish and Norwegian stocks on Chi-X, with resultant clearing and settlement through European Multilateral Clearing Facility N.V. (EMCF), there will be an expansion in the centrally cleared universe of these stocks. All OMX Copenhagen 20 and OBX 25 constituents will be available to trade on Chi-X from tomorrow, Friday 27 th June 2008. The OMX Copenhagen 20 constituents are shown below. The existing five Danish stocks currently traded are highlighted in yellow. CHI-X Name CHI-X RIC CHI-X RIC Bloomberg Bloomberg ISIN Code A P Moller - MAERSKB MAER.I MAERSKb.CO MAERSKbco.CHI MAER IX DK0010244508 Maersk A/S DC A P Moller - MAERSKA DSAA.I MAERSKa.CO MAERSKaco.CHI DSAA IX DK0010244425 Maersk A/S EC A Share Carlsberg CARP.I CARLb.CO CARLbco.CHI CARLB DC CARP IX DK0010181759 A/S D/S Norden DSNO.I DNORD.CO DNORDco.CHI DNORD DC DSNO IX DK0060083210 Danisco A/S DEMC.I DCO.CO DCOco.CHI DCO DC DEMC IX DK0010207497 Danske DDBC.I DANSKE.CO DANSKEco.CHI DANSKE DC DDBC IX DK0010274414 Bank A/S DSV A/S DSVB.I DSV.CO DSVco.CHI DSV DC DSVB IX DK0060079531 FLSmidth & FLBB.I FLS.CO FLSco.CHI FLS DC FLBB IX DK0010234467 Co A/S Genmab GENM.I GEN.CO GENco.CHI FEN DC GENM IX DK0010272202 A/S GN Store GNTC.I GN.CO GNco.CHI GN DC GNTC IX DK0010272632 Nord 1 H Lundbeck LUN.I LUN.CO LUNco.CHI LUN DC LUN IX DK0010287234 A/S NKT Holding NKTC.I NKT.CO NKTco.CHI NKT DC NKTC IX DK0010287663 A/S Nordea NDAC.I NDA.CO NDAco.CHI NDA DC NDAC IX SE0000427361 Bank AB Novo NVOB.I NOVOb.CO NOVObco.CHI NOVOB DC NVOB IX DK0060102614 Nordisk A/S Novozymes NZYM.I NZYMb.CO NZYMbco.CHI NZYMB DC NZYM IX DK0010272129 A/S Sydbank SYDB.I SYDB.CO SYDBco.CHI SYDB DC SYDB IX DK0010311471 A/S Topdanmark TOPC.I TOP.CO TOPco.CHI TOP DC TOPC IX DK0010259530 A/S TrygVesta TRYG.I TRYG.CO TRYGco.CHI TRYG DC TRYG IX DK0060013274 AS Vestas Wind Systems VEST.I VWS.CO VWSco.CHI VWS DC VEST IX DK0010268606 A/S William Demant WIDE.I WDH.CO WDHco.CHI WDH DC WIDE IX DK0010268440 Holding The OBX 25 constituents are shown below. The existing five Norwegian stocks currently traded are highlighted in yellow. CHI-X Name CHI-X RIC CHI-X RIC Bloomberg Bloomberg ISIN Code Acergy SA ACY.I ACY.OL ACYol.CHI ACY NO ACY IX LU0075646355 Aker AKSO.I AKSO.OL AKSOol.CHI AKSO NO AKVR IX NO0010215684 Solutions ASA Aker Yards AKYN.I AKY.OL AKYol.CHI AKY NO AKYN IX NO0010222995 ASA Awilco AWOO.I AWO.OL AWOol.CHI AWO NO AWOO IX NO0010255722 Offshore ASA DnB NOR DNB.I DNBNOR.OL DNBNORol.CHI DNBNOR NO DNB IX NO0010031479 ASA DNO International DNO.I DNO.OL DNOol.CHI DNO NO DNO1 IX NO0003921009 ASA Fred Olsen FOE.I FOE.OL FOEol.CHI FOE NO FOE IX NO0003089005 Energy ASA Frontline Ltd FRO.I FRO.OL FROol.CHI FRO NO FRO IX BMG3682E1277 Golden Ocean Group GOGL.I GOGL.OL GOGLol.CHI GOGL NO GOGL IX BMG4032A1045 Ltd Marine MHG.I MHG.OL MHGol.CHI MHG NO PAN IX NO0003054108 Harvest Norsk Hydro NHY.I NHY.OL NHYol.CHI NHY NO NHY IX NO0005052605 ASA Norske Skogindustrier NSG.I NSG.OL NSGol.CHI NSG NO NSG IX NO0004135633 ASA Orkla ASA ORKA.I ORK.OL ORKol.CHI ORK NO ORKG IX NO0003733800 Petroleum PGS.I PGS.OL PGSol.CHI PGS NO PGS IX NO0010199151 Geo-Services 2 ProSafe SE PRS.I PRSO.OL PRSOol.CHI PRS NO PRS IX CY0100470919 Renewable Energy Corp RECN.I REC.OL RECol.CHI REC NO RECN IX NO0010112675 AS Seadrill Ltd SDRL.I SDRL.OL SDRLol.CHI SDRL NO SDRL IX BMG7945E1057 StatoilHydro STAT.I STL.OL STLol.CHI STL NO STAT IX NO0010096985 ASA Storebrand STB.I STB.OL STBol.CHI STB NO STB IX NO0003053605 ASA Subsea 7 Inc SUBO.I SUB.OL SUBol.CHI SUB NO SUBO IX KYG8549P1081 Tandberg TDDO.I TAA.OL TAAol.CHI TAA NO TDDO IX NO0005620856 ASA Telenor ASA TELO.I TEL.OL TELol.CHI TEL NO TELO IX NO0010063308 TGS Nopec Geophysical NOP.I TGS.OL TGSol.CHI TGS NO NOP1 IX NO0003078800 Co ASA Tomra TOMO.I TOM.OL TOMol.CHI TOM NO TOMO IX NO0005668905 Systems ASA Yara International YARA.I YAR.OL YARol.CHI YAR NO YARA IX NO0010208051 ASA Any queries regarding this notice should be directed to: Name Telephone Email Technical +44 (0)20 7131 3300 [email protected] Operations Trading Surveillance +44 (0)20 7131 3399 [email protected] & Compliance Please be aware, that while every effort has been made to ensure its accuracy, Chi-X Europe Ltd is unable to accept responsibility for any errors in information provided to you in this notice. Chi-X Europe Ltd is regulated by the FSA and registered in England & Wales under company registration no 01651728. 3 .
Load more

Recommended publications
  • Conte Annual Report 2000 / 2001
    Coloplast’s Mission Contents Throughout the world we wish to be perceived as depend- Coloplast in brief 2 able providers of consumable products and services. 5 years’ key figures and ratios 3 Our customers are health care professionals and users. Our primary concern is to improve the quality of life of Board and Group Management 4 individuals suffering from a disabling condition. Management report 5 We respond quickly to market needs to ensure the highest level of customer satisfaction. We strive to offer Financial review 11 preferred product ranges based on innovation, advanced technology and cost-effectiveness. Risk factors 15 Accounting policies 17 All employees must be recognised for their empathy with user needs and dependability in business relations. Profit and loss account 19 It is our ambition to attract and retain the best human Balance sheet 20 resources. Consolidated cash flow statement 22 As individuals and as an organisation we will act respon- Auditors’ report and approvals 23 sibly and be socially and environmentally conscious. Notes 24 We strive to be the best within our businesses, thereby achieving growth and value for the company, the em ploy- ees and shareholders. Stakeholder reporting Annual Report 2000 / 2001 – value creation and knowledge management 32 Customers 33 Employees 38 Society 41 Shareholders 43 Indicators for value drivers and value propositions 48 Artist of the year 50 Group addresses Executives Coloplast Mission Coloplast A/S Coloplast, Conveen, Comfeel, Holtedam 1 Amoena, Sween, Compeed, DK-3050 Humlebæk Assura, Easiflex, EasiCath, Coloplast’s Annual Report for 2000/01 has its own Tel. + 45 49 11 11 11 SpeediCath, Biatain, Contreet, microsite on our corporate website at the address: Fax + 45 49 11 15 55 and Prema are registered trade- E-mail: [email protected] marks of the Coloplast Group.
    [Show full text]
  • Full Portfolio Holdings
    Hartford Multifactor International Fund Full Portfolio Holdings* as of August 31, 2021 % of Security Coupon Maturity Shares/Par Market Value Net Assets Merck KGaA 0.000 152 36,115 0.982 Kuehne + Nagel International AG 0.000 96 35,085 0.954 Novo Nordisk A/S 0.000 333 33,337 0.906 Koninklijke Ahold Delhaize N.V. 0.000 938 31,646 0.860 Investor AB 0.000 1,268 30,329 0.824 Roche Holding AG 0.000 74 29,715 0.808 WM Morrison Supermarkets plc 0.000 6,781 26,972 0.733 Wesfarmers Ltd. 0.000 577 25,201 0.685 Bouygues S.A. 0.000 595 24,915 0.677 Swisscom AG 0.000 42 24,651 0.670 Loblaw Cos., Ltd. 0.000 347 24,448 0.665 Mineral Resources Ltd. 0.000 596 23,709 0.644 Royal Bank of Canada 0.000 228 23,421 0.637 Bridgestone Corp. 0.000 500 23,017 0.626 BlueScope Steel Ltd. 0.000 1,255 22,944 0.624 Yangzijiang Shipbuilding Holdings Ltd. 0.000 18,600 22,650 0.616 BCE, Inc. 0.000 427 22,270 0.605 Fortescue Metals Group Ltd. 0.000 1,440 21,953 0.597 NN Group N.V. 0.000 411 21,320 0.579 Electricite de France S.A. 0.000 1,560 21,157 0.575 Royal Mail plc 0.000 3,051 20,780 0.565 Sonic Healthcare Ltd. 0.000 643 20,357 0.553 Rio Tinto plc 0.000 271 20,050 0.545 Coloplast A/S 0.000 113 19,578 0.532 Admiral Group plc 0.000 394 19,576 0.532 Swiss Life Holding AG 0.000 37 19,285 0.524 Dexus 0.000 2,432 18,926 0.514 Kesko Oyj 0.000 457 18,910 0.514 Woolworths Group Ltd.
    [Show full text]
  • Xtrackers Etfs
    Xtrackers*/** Société d’investissement à capital variable R.C.S. Luxembourg N° B-119.899 Unaudited Semi-Annual Report For the period from 1 January 2018 to 30 June 2018 No subscription can be accepted on the basis of the financial reports. Subscriptions are only valid if they are made on the basis of the latest published prospectus of Xtrackers accompanied by the latest annual report and the most recent semi-annual report, if published thereafter. * Effective 16 February 2018, db x-trackers changed name to Xtrackers. **This includes synthetic ETFs. Xtrackers** Table of contents Page Organisation 4 Information for Hong Kong Residents 6 Statistics 7 Statement of Net Assets as at 30 June 2018 28 Statement of Investments as at 30 June 2018 50 Xtrackers MSCI WORLD SWAP UCITS ETF* 50 Xtrackers MSCI EUROPE UCITS ETF 56 Xtrackers MSCI JAPAN UCITS ETF 68 Xtrackers MSCI USA SWAP UCITS ETF* 75 Xtrackers EURO STOXX 50 UCITS ETF 80 Xtrackers DAX UCITS ETF 82 Xtrackers FTSE MIB UCITS ETF 83 Xtrackers SWITZERLAND UCITS ETF 85 Xtrackers FTSE 100 INCOME UCITS ETF 86 Xtrackers FTSE 250 UCITS ETF 89 Xtrackers FTSE ALL-SHARE UCITS ETF 96 Xtrackers MSCI EMERGING MARKETS SWAP UCITS ETF* 111 Xtrackers MSCI EM ASIA SWAP UCITS ETF* 115 Xtrackers MSCI EM LATIN AMERICA SWAP UCITS ETF* 117 Xtrackers MSCI EM EUROPE, MIDDLE EAST & AFRICA SWAP UCITS ETF* 118 Xtrackers MSCI TAIWAN UCITS ETF 120 Xtrackers MSCI BRAZIL UCITS ETF 123 Xtrackers NIFTY 50 SWAP UCITS ETF* 125 Xtrackers MSCI KOREA UCITS ETF 127 Xtrackers FTSE CHINA 50 UCITS ETF 130 Xtrackers EURO STOXX QUALITY
    [Show full text]
  • The Confusions in Nordic ESG Ratings
    Rating Objectivity: The Confusions in Nordic ESG Ratings ESG Ratings Subjectivity and its Consequences MASTER THESIS WITHIN: Business Administration NUMBER OF CREDITS: 30 ECTS PROGRAM OF STUDY: Civilekonom AUTHOR: John Rydholm & Samuel Schultzberg Bagge TUTOR: Fredrik Hansen & Toni Duras JÖNKÖPING May 2020 Master Thesis within Business Administration Title: Rating Objectivity: The Confusions in Nordic ESG Ratings - ESG Ratings Subjectivity and its Consequences Authors: John Rydholm, Samuel Schultzberg Bagge Tutors: Fredrik Hansen, Toni Duras Date: May 2020 Key terms: ESG, CSR, Ratings, Rating agencies, MSCI, Thomson Reuters, Sustainalytics, RobecoSAM Abstract: Environmental, Social and Governance measurements have significantly increased in usage due to growing concerns for environmental and sustainability problems in today’s world. However, with no commonly agreed-upon criteria for ESG ratings, the scoring measure creates confusion both at the investor and company level. Besides, ESG agencies have different processes and parameters for measuring ESG compliance, which contributes to the problem. The study examines four ESG rating agencies’ rating models and ESG scores to get a better understanding of deviations in ESG scores among Nordic companies. By also studying the correlation amongst ESG scores and market capitalizations in firms, the paper hopes to shed light on if any relationships exist between them. Our results show that the four major ESG raters in the study showed a weak to a non-significant correlation against each other. The maximum correlation found was 0.419 between Thomson Reuters and MSCI. RobecoSAM and MSCI showed the lowest significant correlation at 0.291. Sustainalytics was detected not to show any significant correlation with the other raters.
    [Show full text]
  • Aktienyt Novozymes
    Aktienyt Novozymes Hold Udfordrende markeder dæmper salgsvæksten Uændret Hold-anbefaling siden 20/04/2016 Vi fastholder vores Hold-anbefaling på Novozymes Dagens regnskab er lidt svagere, end vi havde ventet. Hård priskonkurrence i ’Bioenergi’ og økonomisk Analysedato: 10/08/2016 pressede kunder i ’Landbrug og Foder’ dæmper Novozymes’ salgsvækst. Pris- fastsættelsen af Novozymes-aktien afspejler efter vores vurdering Novozymes’ Aktuel kurs kl. 12:11: kortsigtede forretningsmuligheder. 295,00 DKK Salgsvæksten skuffer i årets 2. kvartal Omsætningen på 3.429 mio. kr. i 2. kvartal 2016 er 3,3% dårligere end vores estimat (-3,5% i Begivenhed: forhold til markedsforventningen). Resultatet af primær drift på 961 mio. kr. i 2. kvartal 2016 er 2,9% under vores estimat (-2,6% i forhold til markedsforventningen). I forhold til vores for- 2. kvartalsregnskab ventning er det specielt salget i divisionerne ’Bioenergi’ og ’Landbrug og Foder’, der viser en svagere end ventet udvikling i 2. kvartal. Novozymes justerer salgsprognosen for 2016 i lokal Seneste analyse: valuta. Selskabet venter nu en salgsvækst i lokal valuta på 2-4% i 2016 mod tidligere 3-5%. 05/08/16 – Vækst i ’Vaskemid- Novozymes forventer, at salgsvæksten i danske kroner forbliver uændret på 1-3% i 2016. ler’ – Tilbagegang i ’Bioenergi’ Salgsvæksten i ’Vaskemidler’ overgår vores forventning Den organiske salgsvækst i divisionen ’Vaskemidler’ på 4% i 2. kvartal er lidt bedre end vo- res estimat på 3%. Vi hæfter hos ved, at salget vokser i Asien drevet af øget penetration af Kalender: enzymer i flydende vaskemidler. Yderligere noterer vi os, at den positive salgsudvikling er 26/10/16 – 3.
    [Show full text]
  • Genmab Announces Data to Be Presented at 2017 ASCO Annual Meeting
    Genmab Announces Data to be Presented at 2017 ASCO Annual Meeting Media Release 8 abstracts on Genmab programs scheduled for presentation at ASCO Two daratumumab oral presentations and five daratumumab poster presentations Copenhagen, Denmark; April 20, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that seven daratumumab abstracts have been accepted for presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2 – 6. These abstracts, submitted by our collaboration partner, Janssen Biotech, Inc., include updates for the POLLUX and CASTOR trials, and the first data for a Phase I study evaluating daratumumab with carfilzomib, lenalidomide and dexamethasone in front line multiple myeloma patients, which will be presented in an oral presentation. In addition, descriptions of the Phase Ib/II study of daratumumab plus atezolizumab in non-small cell lung cancer and of our Phase I/II study with HuMax-AXL-ADC are scheduled for poster presentations at the meeting. The titles of the abstracts are currently available on the ASCO website with the full abstracts scheduled to be published on May 17, 2017. “We are very pleased that, once again, a number of abstracts based on exciting work with Genmab’s innovative therapeutic antibody products have been accepted for presentation at the prestigious ASCO conference,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. List of abstracts: Daratumumab: Efficacy Of Daratumumab In Combination with Lenalidomide Plus Dexamethasone (DRd) or
    [Show full text]
  • Honours Programme, Industrial Track Msc Chemical and Biochemical Engineering Honours Programme in Chemical and Biochemical Engineering
    Honours Programme, Industrial Track MSc Chemical and Biochemical Engineering Honours Programme in Chemical and Biochemical Engineering In September 2009 DTU established honours programmes within the context of the regular MSc programmes (see:www.dtu.dk/ english). The programmes are open to highly qualified internation- al and Danish students. You can choose to focus your Honours Programme in Chemical and Biochemical Engineering on industrial research and development by following a special Industrial Track. Industrial Track The superb industrial contacts and the high international standing amongst the faculty of the Department have made it possible to form an industrial track within the Honours Programme. The philosophy is to enable the very best and most motivated stu- dents to gain from high-level, world-class industrial contacts in major Danish enterprises with operations all over the world. In this way we work to open new and exciting career prospects for the students within industrial research, innovation, process design, operation and management. The programme is coordinated with leading international Danish companies. Presently FLSmidth, Lundbeck, Novozymes, Haldor- Topsøe, and Hempel support the programme. Admission to Indus- trial Track is subject to acceptance by a partner company. 2 DTU Special features The Technical University of Denmark (DTU) is Scandinavia’s leading The honours programme, Industrial Track has some special features technical university and one of the top technical universities in Europe. over and above the normal MSc programme. These are: It has outstanding facilities for education and research in a large, open campus just north of Copenhagen. Masters courses are taught in Eng- Mentoring lish, in an innovative and open-minded learning environment.
    [Show full text]
  • Genmab's 2020 Capital Markets
    WELCOME Genmab’s 2020 Capital Markets Day November 13, 2020 Webcast Live from Utrecht and Princeton Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors.
    [Show full text]
  • Second Pre-Clinical Milestone Met in Lundbeck Collaboration - €1 Million Milestone Payment to Genmab
    GENMAB REACHES SECOND MILESTONE IN LUNDBECK COLLABORATION - Second pre-clinical milestone met in Lundbeck collaboration - €1 million milestone payment to Genmab Copenhagen, Denmark; February 10, 2012 – Genmab A/S (OMX: GEN) announced today it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the central nervous system (CNS). The milestone triggers a payment of €1 million to Genmab. Under the collaboration with Lundbeck Genmab creates novel human antibodies to three targets identified by Lundbeck and Lundbeck has access to Genmab’s antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms. Under the terms of the agreement, Genmab received an upfront payment of €7.5 million in October 2010 (approximately DKK 56 million). Lundbeck fully funds the development of the antibodies. If all milestones in the agreement are achieved, the total value of the agreement to Genmab would be approximately €38 million (approximately DKK 283 million), plus single-digit royalties. “We are very pleased to have met the in vitro proof of concept milestone for another target in the Lundbeck collaboration. This partnership is progressing well, with this second milestone coming shortly after we achieved the first preclinical milestone in December last year,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
    [Show full text]
  • 2626667.Pdf (1.837Mb)
    BI Norwegian Business School - campus Oslo GRA 19703 Master Thesis Thesis Master of Science Evaluating the Predictive Power of Leading Indicators Used by Analysts to Predict the Stock Return for Norwegian Listed Companies Navn: Amanda Marit Ackerman Myhre Hadi Khaddaj Start: 15.01.2020 09.00 Finish: 01.09.2020 12.00 GRA 19703 0981324 0983760 Evaluating the Predictive Power of Leading Indicators Used by Analysts to Predict the Stock Return for Norwegian Listed Companies Supervisor: Ignacio Garcia de Olalla Lopez Programme: Master of Science in Business with Major in Accounting and Business Control Abstract This paper studies the predictive power of leading indicators used by interviewed analysts to predict the monthly excess stock returns for some of the most influential Norwegian companies listed on the Oslo Stock Exchange. The thesis primarily seeks to evaluate whether a multiple factor forecast model or a forecast combination model incorporating additional explanatory variables have the ability to outperform a five common factor (FCF) benchmark forecast model containing common factors for the Norwegian stock market. The in-sample and out-of- sample forecasting results indicate that a multiple factor forecast model fails to outperform the FCF benchmark model. Interestingly, a forecast combination model with additional explanatory variables for the Norwegian market is expected to outperform the FCF benchmark forecast model. GRA 19703 0981324 0983760 Acknowledgements This thesis was written as the final piece of assessment after five years at BI Norwegian Business School and marks the completion of the Master of Science in Business program. We would like to thank our supervisor Ignacio Garcia de Olalla Lopez for his help and guidance through this process.
    [Show full text]
  • Jens Howitz (Pdf)
    Ledelsesevaluering og mangfoldighed Jens M. Howitz Managing Director Russell Reynolds Associates Januar 2014 Bestyrelsesprofil under forandring 1999 2013 Hvid, mand, midaldrende Mangfoldighed: Køn, alder, erfaring Homogen profil “Old Boys Network” Overvejende international/global Relationer og kontakter Udvælgelsesproces Dansk Kompetencedrevet Specifik baggrund og indsigt: Tidligere CEO / Generalist • Finans, SCM, Branding, CSR etc. Advokat •Emerging markeder •Brancheforståelse •Uafhængighed FTSE 100 CAC40 DAX AEX OBX OMX C20 ‘09 ‘12 ‘09 ‘12 ‘09 ’12 ‘09 ‘12 ‘09 ‘13 ’09 ’13 Female 11% 21% 8% 22% 5% 10% 14% 20% 39% 38% 10% 16% NEDs ‘Foreign’ 37% 41% 28% 31% 18% 26% 48% 53% 27% 39% 24% 35% NEDs Average Age 57 60 60 61 61 62 62 61 54 52 58 57 2 Virksomheder Novo Nordisk Lundbeck A.P.Møller – Maersk GN Store Nord Danske Bank Jyske Bank Carlsberg Topdanmark Coloplast FLSmidth & Co. Novozymes DONG Energy TDC Danish Crown Pandora Coop Danmark Vestas Wind Systems DLG Tryg Danfoss DSV Grundfos William Demant Holding LEGO Chr. Hansen Holding 3 Bestyrelsesmedlemmer 2013 vs. 2003 Anciennitet i top 25 virksomheder i DK 2013 Anciennitet i top 25 virksomheder i DK 2003 100 45 90 40 80 35 70 30 60 25 Antal Medlemmer Antal Medlemmer 50 Mænd Mænd 20 40 Kvinder Kvinder 15 30 20 10 10 5 0 0 0-3 år 3-6 år 6-9 år 9-12 år 12+ 0-3 år 3-6 år 6-9 år 9-12 år 12+ 4 Bestyrelsesmedlemmers nationalitet, top 25 2013 2003 3% 13% 6% 13% Dansk Dansk Nordisk Nordisk Andet Andet 74% 91% 5 Bestyrelsessammensætning, top 25 2013 2003 Køn: 83,9 % mænd
    [Show full text]
  • Danish Subsidiaries in Argentina Royal Danish Embassy, Buenos Aires
    DANISH SUBSIDIARIES IN ARGENTINA ROYAL DANISH EMBASSY, BUENOS AIRES Date April 2017 Table of Contents APM Terminals (Terminal 4) ........................................................................................ 3 Arla Foods Ingredients S.A. ........................................................................................... 3 Essentia Argentina S.A. .................................................................................................. 3 Chr. Hansen Argentina S.A.I.C .................................................................................... 4 Coloplast de Argentina .................................................................................................... 4 DAMCO ARGENTINA S.A. ........................................................................................ 4 Danfoss Argentina S.A. ................................................................................................... 5 DSV Air & SEA S.A. ......................................................................................................... 5 ESS-FOOD Argentina ..................................................................................................... 5 Exem Trading S.R.L. (Lego Distr.) ............................................................................ 6 Ferring Argentina S.A. .................................................................................................... 6 Foss S.A. .............................................................................................................................
    [Show full text]